Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122034) titled 'A single-arm, multicenter, prospective clinical study on the sequential use of Trastuzumab-rezetecan and Fluzoparib for maintenance treatment in patients with platinum-sensitive recurrence after first-line PARPi treatment for ovarian cancer' on April 8.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
Ovarian cancer
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2026-04-08
Target Sample Size: Test group:34;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/sh...